COG ADVL0314: A PHASE 1 STUDY OF BEVACIZUMAB IN REFRACTORY SOLID TUMORS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This phase I study tests the safety of a new experimental drug called bevacizumab, which is an antibody that works to block the development of new blood vessels. Tumors cannot grow without blood supply through newly formed blood vessels, and laboratory experiments performed with bevacizumab showed that it may block the growth of new blood vessels. Tumors may not be able to grow when exposed to bevacizumab. A safe dose of bevacizumab has already been found in adults, but there have been no trials of bevacizumab in children yet. The goals of this study are to test the safety of bevacizumab, to see what effects (good and bad) it has on children and children's cancer, and to find the highest dose of bevacizumab that can be given to children without causing severe side effects. Other goals of this study are to learn how the body handles the drug, and to better understand the functions in tumor cells that differ from healthy cells. Because the main purpose of this phase I trial is to find the maximum dose of bevacizumab that can be safely given to children, the dose that some patients receive may be too little to have any effect on their tumor, or it may be too high and cause bad side effects. It is not known if this drug, at any dose, will be effective in treating the cancer of patients treated on this study.